Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to gather preliminary data to determine if ranolazine is a safe
and effective treatment for the symptoms of myotonia congenital, paramyotonia congenita, and
myotonic dystrophy type 1. The duration of the study is 5 weeks.